nces Phase II Clinical Trial in
Selected Abstract
Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections.
PARIS, November 12 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced injectable antibacterial, which combines ... November 12, 2008; PR Newswire Europe
Read the full article with a free-trial membership at HighBeam Research
Related Articles No Results Found.
|
